Clinical Trials

Shelf-stable donor milk pioneer Leche and testing firm Tiny Health launch a study to see if a little breast milk can make a big difference for formula-fed babies.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

Kolon TissueGene's revolutionary knee therapy, once a beacon of hope, fails a pivotal Phase 3 trial, raising questions about its future and the broader field.

With promising new data, Nuvation Bio is launching a bold, multi-front clinical strategy for its brain cancer drug. Is this the move that will outmaneuver competitors?

With a new CEO famed for a $2.4B exit and a reverse merger in play, Mentari Therapeutics isn't just developing drugs; it's building a powerhouse.

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

A Dutch med-tech firm's sutureless device, validated in a key trial, could make bypass surgery faster, safer, and more accessible via robotics.

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

With its MASH drug Rezdiffra a certified blockbuster, Madrigal's upcoming Q2 report will reveal if its meteoric rise can be sustained against new rivals.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

As Celldex nears pivotal data for its lead drug, the planned retirement of its long-serving CFO marks a strategic pivot toward becoming a commercial powerhouse.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

As federal mandates push to end decades of stagnation, one company's 'truly real-time' platform offers a foundational fix for drug development.

A startling case study suggests lifelong heat exposure may build resilience against Alzheimer's. Now, medical researchers are turning to infrared saunas.